17.03.2023 • NewsLummus TechnologybutadieneBASF

Lummus Wins Kazakhstan Butadiene Contracts

Lummus Technology has received a contract to supply multiple technologies to Butadiene LLP for a new petrochemical complex in Atyrau, Kazakhstan.

“We are grateful to be selected and provide multiple technologies and solutions to support Butadiene LLP’s growth and expansion,” said Lummus Technology’s president and CEO Leon de Bruyn. “Lummus’ integrated solutions can help grow the economic position of our customer as they execute this important project for Kazakhstan and its downstream industry.”

The scope of the contract includes the technology license and basic engineering for four process units, with Lummus providing its iC4 Catofin, Catadiene, CDMtbe processes and BASF’s butadiene extraction technology. Lummus has been licensing BASF’s butadiene extraction technology for over 30 years.

Once complete, the units will upgrade a mixed butanes feed to produce 85,000 t/y of isobutylene, 120,000 t/y of butadiene, and 40,000 t/y of methyl tert-butyl ether (MTBE). These products will feed Butadiene LLP’s new synthetic rubber production facility and supply the local Kazakhstan transportation fuels market.

Butadiene LLP is a joint venture that was set up by KazMunayGas and Russia’s Tatneft in November 2021 to produce a range of butadiene rubbers. Construction on the complex started last November and completion is scheduled for 2025.

Author: Elaine Burridge, Freelance Journalist

Company

Logo:

Lummus Technology

5825 North Sam Houston Pkwy W #600
77086 Houston, TX
US

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.